Endodynamix Inc

Leap Therapeutics, based in Cambridge, MA, is dedicated to developing targeted and immuno-oncology therapeutics, with a focus on innovative treatments for various cancer types, including gastric, colorectal, and gynecologic cancers. Their lead candidate, DKN-01, is a humanized monoclonal antibody that targets the Dickkopf-1 (DKK1) protein and is currently in clinical development for patients with DKK1-expressing tumors. In addition to DKN-01, Leap Therapeutics is advancing FL-301, which targets Claudin18.2 for gastric and pancreatic cancers, and FL-501, a preclinical candidate that targets the growth and differentiation factor 15 (GDF-15) protein. The company is committed to understanding tumor expression and discovering new therapeutic targets and combinations to improve cancer treatment outcomes. Generated from the website

Seres Health Inc is a biotechnology company based in Cambridge, MA, specializing in microbiome therapeutics. They focus on developing innovative treatments to address various diseases by targeting the microbiome in the human body. Generated from their business information

AVI BioPharma is a biopharmaceutical company that develops drugs to treat life-threatening diseases using its patented third generation antisense technology. It has completed clinical trials with its NeuGene antisense drugs in more than 300 subjects, addressing cardiovascular restenosis, infectious diseases, cancer, polycystic kidney disease and drug metabolism. Its most advanced cardiovascular program is for restenosis, where it has completed Phase II trials, evaluating its drug, Resten-NG. AVI BioPharma is also in a Phase II clinical trial with a drug for Hepatitis C infection and its influenza A drug candidate has been confirmed to have efficacy against avian influenza H5N1 in preclinical studies. AVI BioPharma maintains a location in Portland, Ore.